Nintedanib: all 136 studies that test it

Page 1 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)Not yet recruitingNCT07583589Phase 2
• A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung CancerNot yet recruitingNCT07485920Phase 4
• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingNCT07335562Phase 3
• Nintedanib for Improving Reproductive Outcomes in AdenomyosisNot yet recruitingNCT07162961Phase 3
• Nintedanib Treatment in Unicentric Castleman DiseaseNot yet recruitingNCT06643091Phase 2
• RCT of Nintedanib in Fibrotic SarcoidosisRecruitingNCT06479603Phase 4
• Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung DiseaseRecruitingNCT06297096Phase 3
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2
• Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) PatientsRecruitingNCT04976036Phase 2
• Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary FibrosisRecruitingNCT04541680Phase 3
• Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell TransplantationRecruitingNCT03805477Phase 2
• Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and NintedanibCompletedNCT06717100Phase 1Results posted
• A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the BloodCompletedNCT06070610Phase 1Results posted
• Myositis Interstitial Lung Disease Nintedanib TrialCompletedNCT05799755Phase 4Results posted
• A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)CompletedNCT05285982Phase 3Results posted
• A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung FibrosisCompletedNCT05065190Phase 3Results posted
• A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg CapsuleCompletedNCT04938453Phase 1Results posted
• The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19CompletedNCT04619680Phase 4Results posted
• A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)CompletedNCT04093024Phase 3Results posted
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT03820726Phase 3Results posted
• A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)CompletedNCT03675581Phase 1Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung FibrosisCompletedNCT03313180Phase 3Results posted
• LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal CarcinomaTerminatedNCT03287947Phase 2Results posted
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT02999178Phase 3Results posted
• Study of Nintedanib and Chemotherapy for Advanced Pancreatic CancerTerminatedNCT02902484Phase 1/2Results posted
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentCompletedNCT02788474Phase 4Results posted
• Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung CancerTerminatedNCT02751385Phase 1Results posted
• Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaCompletedNCT02668393Phase 1Results posted
• Influence of Bosentan on the Pharmacokinetics of NintedanibCompletedNCT02667704Phase 1Results posted
• A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationCompletedNCT02606877Phase 4Results posted
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02598193Phase 4Results posted
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung FibrosisCompletedNCT02597933Phase 3Results posted
• Relative Bioavailability of 2 Oral Formulations of NintedanibCompletedNCT02572752Phase 1Results posted
• Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is RecurrentCompletedNCT02568449Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation PneumonitisCompletedNCT02496585Phase 2Results posted
• Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyTerminatedNCT02452463Phase 2Results posted
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02399215Phase 2Results posted
• Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)TerminatedNCT02389764Phase 2Results posted
• Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line ChemotherapyCompletedNCT02300298Phase 1Results posted
• Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02299141Phase 2Results posted
• Nintedanib in Patients With Advanced Esophagogastric CancerCompletedNCT02234596Phase 2Results posted
• LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchTerminatedNCT02231164Phase 3Results posted
• Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy VolunteersCompletedNCT02191865Phase 1Results posted
• Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)CompletedNCT02149108Phase 3Results posted
• Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01979952Phase 3Results posted
• Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy RegimensCompletedNCT01948141Phase 2Results posted
• Nintedanib (BIBF 1120) in MesotheliomaTerminatedNCT01907100Phase 2/3Results posted
• Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male VolunteersCompletedNCT01679613Phase 1Results posted
• BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian CancerCompletedNCT01669798Phase 2Results posted
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Phase 3Results posted
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)CompletedNCT01417156Phase 2Results posted
• BIBF 1120 for Recurrent High-Grade GliomasCompletedNCT01380782Phase 2Results posted
• A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.CompletedNCT01346540Phase 1Results posted
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients IICompletedNCT01335477Phase 3Results posted
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis PatientsCompletedNCT01335464Phase 3Results posted
• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01225887Phase 2Results posted
• Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01170065Phase 2Results posted
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPFCompletedNCT01136174Phase 2Results posted
• Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.CompletedNCT01024920Phase 2Results posted
• Combination of BI6727 (Volasertib) and BIBF1120 in Solid TumorsCompletedNCT01022853Phase 1Results posted
• LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian CancerCompletedNCT01015118Phase 3Results posted
• Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01004003Phase 2Results posted
• Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.CompletedNCT00998296Phase 1Results posted
• A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma PatientsCompletedNCT00987935Phase 2Results posted
• Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLCCompletedNCT00806819Phase 3Results posted
• LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerCompletedNCT00805194Phase 3Results posted
• A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120CompletedNCT00715403Phase 1Results posted
• A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian CancerCompletedNCT00710762Phase 2Results posted
• A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate CancerCompletedNCT00706628Phase 2Results posted
• Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompletedNCT07588646Phase 1
• A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy ParticipantsCompletedNCT07015398Phase 1
• A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on NintedanibCompletedNCT06625489Phase 1
• A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy ParticipantsCompletedNCT06568458Phase 1
• A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy SubjectsCompletedNCT05817240Phase 1
• A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.TerminatedNCT05644600Phase 1
• Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine AdhesionsStatus unknownNCT05635071Phase 2/3
• To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT05383131Phase 1
• Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung DiseaseTerminatedNCT05335278Not applicable
• Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung DiseaseWithdrawnNCT05067517Phase 3
• Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsCompletedNCT04971746Phase 1
• Dedicated Drug-Drug Interaction (DDI) Study in Healthy VolunteersCompletedNCT04939467Phase 1
• To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT04888715Phase 1
• Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaStatus unknownNCT04856111Phase 4
• Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19Status unknownNCT04338802Phase 2
• The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment TrialStatus unknownNCT04161014Phase 2
• Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.CompletedNCT03954782Phase 2
• Management of Progressive Disease in Idiopathic Pulmonary FibrosisCompletedNCT03939520Phase 4
• Continuation of Nintedanib After Single Lung Transplantation in IPF SubjectsTerminatedNCT03562416Phase 2
• Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03513484Phase 1
• A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult SubjectsCompletedNCT03363815Phase 1
• Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaWithdrawnNCT03361319Phase 1/2
• Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2
• Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2CompletedNCT03283007Phase 3
• A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)CompletedNCT03062943Phase 2
• Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or EndometriumStatus unknownNCT02866370Phase 2
• Nintedanib as Switch Maintenance Treatment of Pleural Malignant MesotheliomaTerminatedNCT02863055Phase 2
• Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)WithdrawnNCT02856867Phase 2
• Trial Of Pembrolizumab And NintedanibCompletedNCT02856425Phase 1
• Study of Nintedanib Plus Bevacizumab in Advanced Solid TumorsCompletedNCT02835833Phase 1

← Nintedanib overview